News & Updates

In a real-world study presented at IDWeek 2023, dalbavancin has been shown to be an effective treatment alternative for patients with invasive gram-positive infections.

The selective farnesoid-X receptor agonist obeticholic acid appears to improve symptoms of low phospholipid-associated cholelithiasis (LPAC) syndrome in patients who have inadequate response or intolerance to ursodeoxycholic acid, as shown in a small study.

The multikinase inhibitor anlotinib appears to have promising antitumour activity in the treatment of locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma while having an acceptable safety profile, as shown in a phase II study.

Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.